A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

被引：5

作者：

Hong, M. H. ^{[1
]}

Spira, A. I. ^{[2
]}

Lee, K. H. ^{[3
]}

Cho, E. K. ^{[4
]}

Han, J-Y. ^{[5
]}

Shim, B. Y. ^{[6
]}

Lee, J-S. ^{[7
]}

Kao, S. C-H. ^{[8
]}

Kim, S-W. ^{[9
]}

Khattak, A. ^{[10
]}

Patel, M. ^{[11
]}

Xu, R. ^{[11
]}

Wang, J. ^{[11
]}

Ariazi, E. ^{[12
]}

Daemen, A. ^{[12
]}

Maneval, E. Chow ^{[11
]}

Multani, P. S. ^{[11
]}

Patel, R. ^{[11
]}

Ahn, M-J. ^{[13
]}

机构：

[1] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[2] Virginia Canc Specialist & Next Oncol, Res Inst, Fairfax, VA USA

[3] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea

[4] Gachon Univ, Dept Internal Med, Gil Hosp, Incheon, South Korea

[5] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea

[6] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Suwon, South Korea

[7] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea

[8] Chris OBrien Lifehouse, Med Oncol Dept, Camperdown, NSW, Australia

[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[10] Hollywood Med Ctr, One Clin Res, Med Oncol, Nedlands, WA, Australia

[11] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA

[12] ORIC Pharmaceut Inc, Translat Med, San Diego, CA USA

[13] Sungkyunkwan Univ, Dept Hematol Oncol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

来源：

关键词：

D O I：

10.1016/j.annonc.2023.09.2366

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1333P

引用

页数：1